Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: August 25, 2004
Last updated: March 10, 2015
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2004
  Primary Completion Date: September 2004 (Final data collection date for primary outcome measure)